The influence of corticosteroids on the release of novel biomarkers in human endotoxemia by de Kruif, Martijn D. et al.
Intensive Care Med (2008) 34:518–522
DOI 10.1007/s00134-007-0955-x BRIEF REPORT
MartijnD. de Kruif
LucienneC. Lemaire
IdaA. Giebelen
Joachim Struck
NilsG. Morgenthaler
Jana Papassotiriou
PeterJ. Elliott
Tom van der Poll
The inﬂuence of corticosteroids on the release
of novel biomarkers in human endotoxemia
Received: 8 June 2007
Accepted: 31 October 2007
Published online: 14 December 2007
© The Author(s) 2007
This article is discussed in the editorial
available at: http://dx.doi.org/10.1007/
s00134-007-956-9.
This study was supported by research
funding from CombinatoRx, Inc.,
Cambridge, MA, USA. One of the authors
(Peter J. Elliott) was employed by
CombinatoRx at the time of study design
and completion. Currently, he is employed
elsewhere but he is still a stockholder of
CombinatoRx. Joachim Struck, Nils G.
Morgenthaler and Jana Papassotiriou are
employed by Brahms AG, Hennigsdorf,
Germany.
M.D. de Kruif () · I.A. Giebelen ·
T. van der Poll
Academic Medical Center, Center for
Experimental and Molecular Medicine,
Room G2-132,
Meibergdreef 9, 1105 Amsterdam,
The Netherlands
e-mail: m.d.dekruif@amc.uva.nl
L.C. Lemaire
University Medical Center Utrecht,
Department of Anesthesiology,
P.O. Box 85500, 3508 Utrecht,
The Netherlands
I.A. Giebelen · T. van der Poll
Academic Medical Center, University of
Amsterdam, Center for Infection and
Immunity Amsterdam,
Meibergdreef 9, 1105 Amsterdam,
The Netherlands
J. Struck · N.G. Morgenthaler ·
J. Papassotiriou
Brahms AG, Research Department,
Neuendorfstrasse 25,
16761 Hennigsdorf/Berlin, Germany
P.J. Elliott
CombinatoRx, Inc.,
245 st., 16th ﬂoor,
Cambridge 02142, MA, USA
P.J. Elliott
Sirtris Pharmaceuticals,
790 Memorial Drive,
Cambridge 02139, MA, USA
Abstract Objective: Sepsis inter-
vention studies need better patient
stratiﬁcation methods, and one way
to realize this is the introduction
of stable biomarkers. A set of re-
cently developed novel biomarkers,
based upon precursor-fragments of
short-lived hormones, was previously
shown to be increased during sepsis.
However, it is not known whether
these biomarkers are inﬂuenced by
sepsis intervention strategies. There-
fore we investigated the markers
in a model of human endotoxemia
intervened by increasing doses of
prednisolone. Design and setting:
Prospective, open-label study in
a specialized clinical research unit
of a university hospital. Subjects:
Thirty-two healthy male volunteers.
Interventions: Subjects received
prednisolone orally at doses of 0,
3, 10 or 30mg (n=8 per group)
at 2h before intravenous injection
of Escherichia coli lipopolysac-
charide (LPS) (4ng/kg). Blood
samples were drawn during 24 h after
LPS injection. Measurements and
results: LPS injection caused an
increase in levels of midregional
pro-adrenomedullin (MR-proADM),
midregional pro-atrial natriuretic pep-
tide (MR-proANP), C-terminal pro-
arginine–vasopressin (CT-proAVP)
andprocalcitonin(PCT).Prednisolone
caused a dose dependent inhibition
of MR-proADM, MR-proANP and
CT-proAVP levels. Conclusions:
These results show that a set of novel,
highly stable sepsis biomarkers was
increased during human endotoxemia
and was dose-dependently inhibited
by corticosteroid pre-treatment.
Keywords Corticosteroids · Biologi-
cal markers · Endotoxin · Sepsis519
Introduction
During the past decade numerous sepsis intervention
strategies have been introduced; only few of them, how-
ever, have shown beneﬁcial effects. Major problems in
sepsis intervention trials were mixed results and unclear
risk stratiﬁcation methods. The lack of clear stratiﬁcation
methods was especially disturbing, since the effectiveness
of intervention in these studies correlated closely with
disease severity and risk of mortality [1]. Within this
context, there is a need for biomarkers to predict disease
severity and mortality risk.
During sepsis a wide range of inﬂammatory proteins
is released and in theory all could be used as a biomarker.
The vast majority of these proteins is biologically active
though and as a consequence rapidly cleared from the cir-
culation. A promising new approach is the measurement
of stable prohormone fragments of bioactive peptide-
hormones [2–4]. In theory, these fragments often have no
known biological function during sepsis and are therefore
less rapidly cleared and less sensitive to small homeostatic
changes [5–7].
The most prominent prohormone sepsis marker is
procalcitonin (PCT), which represents the precursor
hormone of calcitonin. Its diagnostic and prognostic
properties were superior to C-reactive protein (CRP)
in multiple studies [8]. In addition, PCT responded to
sepsis intervention strategies and represented a promising
marker for monitoring of treatment effect [9,10]. In
recent years, additional assays have been developed for
measurement of stable prohormone fragments, such as
mid-regional pro-adrenomedullin (MR-proADM) [5],
derived from the precursor of adrenomedullin (ADM);
mid-regional pro-atrial natriuretic peptide (MR-proANP),
derived from the precursor of atrial natriuretic peptide
(ANP) [6]; and C-terminal proAVP (CT-proAVP), de-
rived from the precursor of arginine–vasopressin (AVP;
also known as the antidiuretic hormone) [7]. Levels of
these biomarkers were higher in samples from patients
with sepsis [2–4]. Yet it is not known whether these
levels are inﬂuenced by a potential therapeutic sepsis
intervention. In order to investigate the response of the
novel biomarkers to a sepsis intervention strategy we
applied the model of human endotoxemia and pre-treated
subjects by increasing doses of corticosteroids, which
is one of the few relatively successful, and among the
most cost-effective, septic shock intervention strategies to
date [11].
Methods
Subjects and study design
The study was designed according to the requirements
of the Declaration of Helsinki and approved by the
institutional scientiﬁc and ethics committees, and written
informed consent was obtained from all subjects. The
study was performed simultaneously with an investigation
of the effects of prednisolone on activation of the cytokine
network, coagulation and hemodynamic variables in the
same cohort [12]. Thirty-two healthy male volunteers
[mean (± SE) age 23.9± 0.7 years] were admitted to
a hospital clinical research unit. Screening tests were
all normal. Prednisolone (prednisolone sodium phos-
phate oral solution 5 mg/ml; prepared by institutional
pharmacy) was administered orally at a dose of 0, 3,
10 or 30mg (n= 8 per group) at 2h prior to LPS in-
jection. All participants were challenged at t =0 h with
LPS (Escherichia coli lipopolysaccharide, lot G; US
Pharmacopeia, Rockville, MD) as a bolus intravenous
injection at a dose of 4ng/kg, which is a standardized
dose [13].
Assays
Blood was collected at intervals from 2h before LPS
injection to 24h thereafter. Blood was immediately cen-
trifuged (4°C, 10min, 3000rpm) and plasma was stored
at –20°C until assayed. Uptake of orally administered
prednisolone was measured by HPLC-MS/MS technology
(CombinatoRx, Inc., Boston, MA, USA). MR-proADM,
MR-proANP, CT-proAVP and PCT were measured by
chemiluminescence label-coated tube-based sandwich
immunoassays (Brahms Diagnostica, Berlin, Germany) as
previously described [5–7, 14].
Statistical analysis
Differences between treatment groups were analyzed
using a non-parametric mixed model approach (repeated-
measures ANOVA). The effects reported are treatment
effects adjusted for time effects. p values <0.05 were
considered statistically signiﬁcant. Values presented are
given as mean± SE.
Results
Pharmacokinetic data
As shown in Fig. 1, uptake of orally administered
prednisolone was demonstrated by a dose-dependent
increase in plasma levels during endotoxemia. The lev-
els peaked from 1h before LPS administration to 1h
after LPS administration (peak levels 302±34ng/ml,
190±19ng/ml and 71±5ng/ml in the groups re-
ceiving prednisolone 30, 10 and 3mg respectively;
t =–1h) .520
Fig.1 Prednisolone. Mean (±SE) values of prednisolone concen-
trations after LPS administration (4ng/kg IV, t=0h) to healthy male
volunteers, preceded by oral administration of prednisolone 3mg
(circles), 10mg (triangles), or 30mg (squares)a tt=–2.5h
Novel prohormone biomarkers
MR-proADM levels increased after LPS administration
from 0.31±0.02nmol/l at baseline to a peak value of
1.05± 0.11nmol/l in the control group at t = 4h (Fig.2).
The rise was inhibited after prednisolone30mg and 10mg
Fig.2 Novel prohormone bio-
markers. Mean (±SE) values of
MR-proADM, MR-proANP,
CT-proAVP and PCT after LPS
administration (4ng/kg IV,
t=0h) to healthy male volun-
teers, preceded by oral administ-
ration of prednisolone 3mg
(open circles), 10mg (triangles),
30mg (squares) or, in the control
group, 0mg (ﬁlled circles)a t
t=–2.5h. *p<0.05 vs. control
group. NS, non signiﬁcant
pre-treatment (levels at t =4h: 0.65±0.06nmol/l and
0.65±0.1nmol/l respectively; p<0.05), but not after the
low dose of prednisolone 3mg. MR-proANP levels rose
from 42.4±2.2pmol/l at baseline to 118.4± 17.2pmol/l
in the control group at t = 4h. These levels were re-
duced after prednisolone 30mg and 10mg (peak levels:
91.5±9.9pmol/l and 64.8± 5.6pmol/l at t =2h and
t = 4h, respectively; p<0.05). CT-proAVP levels
showed a modest increase from 12.5± 4.0pmol/l to
18.0±4.8pmol/l in the control group at t =4h. The
rise was inhibited after prednisolone 30mg (peak level:
6.1± 1.0pmol/l; p<0.05) and not signiﬁcantly changed
by 10mg (peak level: 10.6±3.4 pmol/l; p<0.1). In
contrast, prednisolone 3mg pre-treatment was asso-
ciated with enhanced CT-proAVP release (peak level
34.7±11.5pmol/l; p< 0.05). PCT levels increased from
a baseline level of 0.04±0.02ng/ml to a peak value
of 16.7± 2.6ng/ml in the control group. Peak PCT
levels all occurred at t = 24h and were not signiﬁcantly
affected by prednisolone pre-treatment (11.9± 3.0ng/ml,
13.1±2.5ng/ml and 17.6±3.5ng/ml in the 30, 10 and
3mg group, respectively).
Discussion
The primary objective of this study was to determine the
effect of increasing doses of prednisolone on the release
of novel biomarkers during human endotoxemia. We show521
here that prednisolone pharmacologic concentrations
peaked at the time of LPS infusion and that the release
of MR-proADM, MR-proANP and CT-proAVP was sub-
sequently inhibited in a dose-dependent way. The levels
of PCT were not signiﬁcantly inhibited within the study
period of 24 h. However, previously inhibition of PCT
was shown by anti-inﬂammatory agents within a period
of 168h [9]. The levels of CT-proAVP were, remarkably,
increased after prednisolone 3mg, yet the reason for this
remains unclear because the pattern was unique to this
biomarker.
The increased levels of MR-proANP, MR-proADM
and CT-proAVP reﬂect activation of their mature counter-
parts. Difﬁculties in measurement of the mature hormones
made it difﬁcult to determine their roles during sep-
sis [5–7]. The currently investigated biomarkers are
produced after proteolytic processing of the same pro-
hormone precursors as the mature hormones; thus, they
reﬂect production levels of mature hormones in stoichio-
metric concentrations [7,15]. In theory, the biomarker
assays may measure levels of both cut prohormone
fragments and full-length prohormones. However, the
meaning of this relationship remains unclear in plasma
because no well-deﬁned methods are currently available
for measurement of full-length prohormone plasma
levels.
The biomarker levels in this study were dose-
dependently inﬂuenced by corticosteroid intervention,
which is important for treatment effect monitoring. The
development of new biomarkers is needed for improve-
ment of sepsis stratiﬁcation methods, which inﬂuence
trial outcomes. Several sepsis intervention strategies
have shown promise [16]; in this study corticosteroids
were selected because they aim primarily at inhibition
of the immune response, and for this intervention in
particular, effects are dose-dependent and improvement of
patient stratiﬁcation methods is urgently needed [11,17].
Prednisolone is among the most frequently applied corti-
costeroids [18]; the oral route is convenientand potentially
safer than intravenous administration [19].
The doses of prednisolone used in our model were
chosen according to common dose regimens for pred-
nisolone [18]. These doses were relatively low (equivalent
to 12, 40 and 120mg hydrocortisone) in comparison
to doses used for sepsis intervention (hydrocortisone
200–300mg per day), yet sufﬁcient to reduce the release
of the investigated biomarkers during endotoxemia. Of
note, it has been demonstrated that the effects of orally
administered doses of prednisolone do not differ from
those of comparable doses of intravenously administered
hydrocortisone [20].
The human endotoxemia model differs from sepsis in
many aspects: it uses a single-dose drug intervention and
bolus intravenous challenge of LPS, it is self-limiting, and
it lacks an infectious source [13]. The study subjects are
healthy young people not using any co-medication. The
intervention must be administered before LPS injection in
order to reach clinically relevant drug concentrations dur-
ingendotoxemiabecauseLPS is extremelyquicklycleared
from the circulation. Due to these differences, data cannot
be directly extrapolated to the sepsis ﬁeld and must always
be conﬁrmed in patient studies. Nonetheless, the model is
the best available in healthy humans and has proven useful
to obtain a proof of principle of the actions of drugs and/or
to study mechanismsthat contribute to the activation of in-
ﬂammatory pathways [13]. With these limitations in mind,
wedemonstrateherethatthelevelsofthenovelbiomarkers
MR-proADM, MR-proANP, CT-proAVP and PCT are all
increased after LPS injection, and that the levels of MR-
proADM, MR-proANP and CT-proAVP can be inhibited
by prednisolone. These results add to their potential as
biomarkers in sepsis.
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